Inhibition effect of Entecavir on hepatitis B virus DNA in serum and peripheral blood mononuclear cells of posttransplant patients

YANG Yang,JIANG Hua,LI Hua,LU Min-qiang,CAI Chang-jie,XU Chi,ZHANG Jian,WANG Gen-shu,YI Shu-hong,ZHANG Jun-feng,ZHANG Qi,JIANG Nan,ZHANG Ying-cai,HEI Zi-qing,CHEN Gui-hua

DOI: https://doi.org/10.3969/j.issn.1674-3903.2009.01.006

2009-01-01

Abstract:Objective To explore the inhibition effect of Entecavir on hepatitis B virus(HBV) DNA in serum and peripheral blood mononuclear cells(PBMCs) of patients with HBV-related end-stage liver disease after transplantation.Methods From August to December 2007,20 HBsAg positive liver graft recipients(perioperative group) were treated with Entecavir 0.5 mg/d and additional intramuscular hepatitis B immunoglobulin(HBIG) for prophylaxis of HBV recurrence.HBV DNA in serum and PBMCs was quantified by specific real-time fluorescence PCR 4 times(on the day before operation and in 1,4and 12 weeks after transplantation).Another 34 patients(retrospective group) who underwent liver transplantation from August 2006 to August 2007 and were treated with Entecavir were followed up from 4.0 to 22.5 months.HBV DNA copies in serum and PBMCs were quantified by the same method.Results In the perioperative group,HBV DNA in serum became negative in all 20 cases during Entecavir treatment.The positive rates of HBV DNA in PBMCs on the day before operation and in 1,4 and 12 weeks after liver transplantation(LT) were 85.0%(17/20),45.0%(9/20),45.0%(9/20) and 40.0%(8/20),respectively.Significant difference in the positive rates of HBV DNA in PBMCs was noted between the 1-week posttransplant group and the preoperative group(P=0.004,χ2 test),but no significant difference between any posttransplant groups.The level of HBV DNA in the PBMCs of 4 times were 104.07±2.07,101.69±1.96,101.51±1.72 and 101.30±1.63 copies/106 cells,respectively.The level of the 1-week posttransplant group was significantly lower than that of the preoperative group(P=0.01),but the decrease became no significant difference 4 weeks after transplantation.The retrospective group had been traced no HBV recurrence on an average follow-up period of 13.6 months(the positive rate of HBV DNA in serum was 0).The average positive rate in the PBMCs was 32.4%(11/34)and the level of HBV DNA in the PBMCs was 101.03±0.26 copies/106 cells.Conclusions Entecavir has remarked inhibitory effect on HBV DNA both in serum and PBMCs of posttransplant patients.However it cannot eliminate all the HBV in PBMCs,as the level of HBV DNA fluctuated in a very low range 4 weeks after transplantation.